CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced
results of the voting at its 2011 Annual Meeting of Shareholders.
At the meeting, shareholders re-elected director nominees Matthew W.
Emmens and Wayne J. Riley, M.D. and elected nominee Margaret C. McGlynn
to the company's board of directors. Their terms will expire at the 2014
Annual Meeting of Shareholders. Ms. McGlynn most recently served as
President, Global Vaccines and Infectious Diseases, for Merck & Co.,
Inc. In her nearly three decades at Merck, Ms. McGlynn held a number of
leadership roles focused on marketing, sales and managed care activities
for Merck's portfolio of medicines. She is a member of the National
Industrial Advisory Committee at the University at Buffalo School of
Pharmacy and Pharmaceutical Sciences and holds a B.S. in Pharmacy and an
M.B.A. in Marketing from the State University of New York at Buffalo.
The addition of Ms. McGlynn brings the number of Vertex board members to
eight.
"Ms. McGlynn will provide our Board with invaluable commercial expertise
as we await the approval of INCIVEK for people with hepatitis C," said
Matthew Emmens, Vertex's Chairman, President and Chief Executive
Officer. "I welcome Margie to our Board and look forward to her
contributions at this exciting time for our company."
Also at today's Annual Meeting, Vertex shareholders voted in favor of
the compensation of Vertex's named executive officers and voted for the
next advisory vote on the company's executive compensation program to be
conducted next year. Shareholders also ratified the selection of Ernst &
Young LLP to serve as Vertex's independent registered public accounting
firm for the year ending December 31, 2011.
About Vertex
Vertex creates new possibilities in medicine. Our team aims to discover,
develop and commercialize innovative therapies so people with serious
diseases can lead better lives.
Vertex scientists and our collaborators are working on new medicines to
cure or significantly advance the treatment of hepatitis C, cystic
fibrosis, epilepsy and other life-threatening diseases.
Founded more than 20 years ago in Cambridge, MA, we now have ongoing
worldwide research programs and sites in the U.S., U.K. and Canada.
INCIVEKTM is a trademark of Vertex Pharmaceuticals
Incorporated.
VRTX-GEN
Vertex Contacts:
Investors
Michael Partridge,
617-444-6108
or
Lora Pike, 617-444-6755
or
Matthew
Osborne, 617-444-6057
or
Media
Zachry Barber, 617-444-6992
or
mediainfo@vrtx.com
Source: Vertex Pharmaceuticals Incorporated
News Provided by Acquire Media
